0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV74.87%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma39.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Standard BioTools Stock Discussion
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Benzinga· 1 min ago
No comment yet